drugset / Trial / NCT00160069

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer

NCT00160069

Phase 2 Completed 128 enrolled Bayer
RandomizedSingle-groupOpen-labelTreatment

Summary

Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.

Timeline

Start
2005-08
Primary completion
2008-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sagopilone Small molecule 16 mg/m2
Subject Sagopilone Small molecule 22 mg/m2